ADXS DUAL - Advaxis

Drug Profile

ADXS DUAL - Advaxis

Alternative Names: ADXS-DUAL; Second generation axalimogene filolisbac

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Recombinant fusion proteins
  • Mechanism of Action Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer

Most Recent Events

  • 16 Mar 2018 An investigator-sponsored phase II trial is planned for Head and neck cancer (Metastatic disease) in 2018
  • 21 Dec 2017 Advaxis has patents pending for ADXS DUAL in countries worldwide
  • 11 Sep 2017 Advaxis plans a clinical trial of ADXS DUAL in combination with nivolumab for Cervical cancer (Combination therapy, Metastatic disease, Second line therapy or greater) in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top